The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
In chemistry, racemization is a conversion, by heat or by chemical reaction, of an optically active compound into a racemic (optically inactive) form. This creates a 1:1 molar ratio of enantiomers and is referred to as a racemic mixture (i.e. contain equal amount of (+) and (−) forms). Plus and minus forms are called dextrorotation and levorotation. The D and L enantiomers are present in equal quantities, the resulting sample is described as a racemic mixture or a racemate. Racemization can proceed through a number of different mechanisms, and it has particular significance in pharmacology in as much as different enantiomers may have different pharmaceutical effects.
A 2023 meta-analysis found that racemic ketamine, particularly at higher doses, is more effective than esketamine in reducing depression severity, with more sustained benefits over time. No biomarker has been validated to predict ketamine’s antidepressant response; it may modulate depression-associated neurocircuitry and inflammatory pathways. Ketamine appears to provide rapid (<12 h) and sustained (up to 1–2 weeks) reduction in anxiety across various clinical settings, with improvements correlating with depression improvements but not with peak dissociation. Ketamine has shown potential for rapid and tolerable symptom relief in obsessive-compulsive disorder, but evidence is limited and inconsistent. Several systematic reviews and meta-analyses suggest ketamine may produce short-term (≈ 24 hr) reductions in post-traumatic stress disorder symptoms, but overall evidence quality is low, long-term effects are unclear, and side effects occur. Ketamine shows promising short-term effects in reducing withdrawal, cravings, and improving abstinence across substance use disorders, especially when combined with therapy; however, evidence remains limited and heterogeneous, with unresolved concerns about optimal dosing, long-term safety, and misuse risk. Ketamine, especially when combined with psychotherapy, shows potential to reduce alcohol and cocaine use, but evidence is limited, mixed, and low-quality, with inconclusive results for opioids.
=== Molten oxide electrolysis === Molten oxide electrolysis (MOE) uses electrolysis of molten iron oxide to yield metallic iron. It is studied in laboratory-scale experiments and is proposed as a method for industrial iron production that has no direct emissions of carbon dioxide. It uses a liquid iron cathode, an anode formed from an alloy of chromium, aluminium and iron, and the electrolyte is a mixture of molten metal oxides into which iron ore is dissolved. The current keeps the electrolyte molten and reduces the iron oxide. Oxygen gas is produced in addition to liquid iron. The only carbon dioxide emissions come from any fossil fuel-generated electricity used to heat and reduce the metal.
Sources: en.wikipedia.org
== Solvation == Individual surfactant molecules that are in the system but are not part of a micelle are called "monomers". Micelles represent a molecular assembly, in which the individual components are thermodynamically in equilibrium with monomers of the same species in the surrounding medium. In water, the hydrophilic "heads" of surfactant molecules are always in contact with the solvent, regardless of whether the surfactants exist as monomers or as part of a micelle. However, the lipophilic "tails" of surfactant molecules have less contact with water when they are part of a micelle—this being the basis for the energetic drive for micelle formation. In a micelle, the hydrophobic tails of several surfactant molecules assemble into an oil-like core, the most stable form of which having no contact with water. By contrast, surfactant monomers are surrounded by water molecules that create a "cage" or solvation shell connected by hydrogen bonds. This water cage is similar to a clathrate and has an ice-like crystal structure and can be characterized according to the hydrophobic effect. The extent of lipid solubility is determined by the unfavorable entropy contribution due to the ordering of the water structure according to the hydrophobic effect. Micelles composed of ionic surfactants have an electrostatic attraction to the ions that surround them in solution, the latter known as counterions.
CD98 is a glycoprotein that is a heterodimer composed of SLC3A2 and SLC7A5 that forms the large neutral amino acid transporter (LAT1). LAT1 is a heterodimeric membrane transport protein that preferentially transports branched-chain (valine, leucine, isoleucine) and aromatic (tryptophan, tyrosine, phenylalanine) amino acids. LAT is highly expressed in brain capillaries (which form the blood–brain barrier) relative to other tissues. A functional LAT1 transporter is composed of two proteins encoded by two distinct genes:
Electron-transfer dissociation (ETD) is a method of fragmenting multiply-charged gaseous macromolecules in a mass spectrometer between the stages of tandem mass spectrometry (MS/MS). Similar to electron-capture dissociation, ETD induces fragmentation of large, multiply-charged cations by transferring electrons to them. ETD is used extensively with polymers and biological molecules such as proteins and peptides for sequence analysis. Transferring an electron causes peptide backbone cleavage into c- and z-ions while leaving labile post translational modifications (PTM) intact. The technique only works well for higher charge state peptide or polymer ions (z>2). However, relative to collision-induced dissociation (CID), ETD is advantageous for the fragmentation of longer peptides or even entire proteins. This makes the technique important for top-down proteomics. The method was developed by Hunt and coworkers at the University of Virginia.
Sources: en.wikipedia.org
The main isotopes of argon found on Earth are 40Ar (99.6%), 36Ar (0.34%), and 38Ar (0.06%). Naturally occurring 40K, with a half-life of 1.25×109 years, decays to stable 40Ar (11.2%) by electron capture or positron emission, and also to stable 40Ca (88.8%) by beta decay. These properties and ratios are used to determine the age of rocks by K–Ar dating. In Earth's atmosphere, 39Ar is made by cosmic ray activity, primarily by neutron capture of 40Ar followed by two-neutron emission. In the subsurface environment, it is also produced through neutron capture by 39K, followed by proton emission. 37Ar is created from the neutron capture by 40Ca followed by an alpha particle emission as a result of subsurface nuclear explosions. It has a half-life of 35 days. Between locations in the Solar System, the isotopic composition of argon varies greatly. Where the major source of argon is the decay of 40K in rocks, 40Ar will be the dominant isotope, as it is on Earth. Argon produced directly by stellar nucleosynthesis is dominated by the alpha-process nuclide 36Ar. Correspondingly, solar argon contains 84.6% 36Ar (according to solar wind measurements), and the ratio of the three isotopes 36Ar : 38Ar : 40Ar in the atmospheres of the outer planets is 8400 : 1600 : 1. This contrasts with the low abundance of primordial 36Ar in Earth's atmosphere, which is only 31.5 ppmv (= 9340 ppmv × 0.337%), comparable with that of neon (18.18 ppmv) on Earth and with interplanetary gasses, measured by probes.
Long after the Cisplatine War that resulted in the independence of Uruguay, Brazil won three international wars during the 58-year reign of Pedro II: the Platine War, the Uruguayan War and the devastating Paraguayan War, the largest war effort in Brazilian history. Although there was no desire among the majority of Brazilians to change the country's form of government, on 15 November 1889, in disagreement with the majority of the Imperial Army officers, as well as with rural and financial elites, the monarchy was overthrown by a military coup. A few days later, the national flag was replaced with a new design that included the national motto "Ordem e Progresso", influenced by positivism. 15 November is now Republic Day, a national holiday.
As distressing as these border conflicts were, the Polish–Soviet War of 1919–1921 was the most important series of military actions of the era. Piłsudski had entertained far-reaching anti-Russian cooperative designs in Eastern Europe, and in 1919 the Polish forces pushed eastward into Lithuania, Belarus and Ukraine by taking advantage of the Russian preoccupation with a civil war, but they were soon confronted with the Soviet westward offensive of 1918–1919. Western Ukraine was already a theater of the Polish–Ukrainian War, which eliminated the proclaimed West Ukrainian People's Republic in July 1919. In the autumn of 1919, Piłsudski rejected urgent pleas from the former Entente powers to support Anton Denikin's White movement in its advance on Moscow. The Polish–Soviet War proper began with the Polish Kiev offensive in April 1920. Allied with the Directorate of Ukraine of the Ukrainian People's Republic, the Polish armies had advanced past Vilnius, Minsk and Kiev by June. At that time, a massive Soviet counter-offensive pushed the Poles out of most of Ukraine. On the northern front, the Soviet army reached the outskirts of Warsaw in early August. A Soviet triumph and the quick end of Poland seemed inevitable. However, the Poles scored a stunning victory at the Battle of Warsaw (1920). Afterwards, more Polish military successes followed, and the Soviets had to pull back. They left swathes of territory populated largely by Belarusians or Ukrainians to Polish rule. The new eastern boundary was finalized by the Peace of Riga in March 1921.
== Views on religion == Crick referred to himself as a humanist, which he defined as the belief "that human problems can and must be faced in terms of human moral and intellectual resources without invoking supernatural authority." He publicly called for humanism to replace religion as a guiding force for humanity, writing:
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.